miR-27a-3p regulates proliferation and apoptosis of colon cancer cells by potentially targeting BTG1

CHANG SU1*, DONG-PING HUANG2*, JIAN-WEN LIU3, WEI-YAN LIU1 and YI-OU CAO1

1Department of Surgery, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai 201199; 2Department of Surgery, People’s Hospital of Putuo District, Shanghai 200060; 3Department of Molecular and Cellular Pharmacology, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, P.R. China

Received June 21, 2018; Accepted May 13, 2019

DOI: 10.3892/ol.2019.10629

Abstract. microRNA (miR/miRNA)-27a-3p has been reported to be abnormally expressed in various types of cancer, including colorectal cancer (CRC). B-cell translocation gene 1 (BTG1) has also been implicated with CRC. However, the association between miR-27a-3p and BTG1 in CRC, to the best of our knowledge, has not been investigated. In order to assess whether miR-27a-3p is associated with CRC, reverse transcription-quantitative PCR was performed on 20 paired CRC and paracancerous tissues for miRNA analysis. For the screening and validation of miR-27a-3p expression in colon cancer, several colon cancer cell lines (HCT-116, HCT8, SW480, HT29, LOVO and Caco2) and the normal colorectal epithelial cell line NCM460 were examined. The highest expression levels of miR-27a-3p were detected in the HCT-116, which was selected for further experimentation. The HCT-116 cells were divided into control, miR-27a-3p mimic and inhibitor groups, and cell proliferation was tested using an MTT assay. Additionally, miR-27a-3p inhibitor/mimic or BTG1 plasmid were transfected into the HCT-116 cells, and flow cytometry was performed to analyze cell cycle distributions. TUNEL analysis was performed to detect apoptosis. Protein levels of factors in the downstream signaling pathway mediated by miR-27a-3p [ERK/mitogen-activated extracellular signal-regulated kinase (MEK)] were detected. miR-27a-3p was revealed to be overexpressed in human CRC tissues and colon cancer cell lines. Knockdown of miR-27a-3p suppressed proliferation of HCT-116 cells and apoptosis was increased. It further markedly upregulated expression levels of BTG1 and inhibited activation of proteins of the ERK/MEK signaling pathway. In addition, overexpression of BTG1 in HCT-116 cells triggered G1/S phase cell cycle arrest and increased apoptosis via the ERK/MEK signaling pathway. In conclusion, the present study demonstrated that the effects of miR-27a-3p on colon cancer cell proliferation and apoptosis were similar to those of the tumor suppressor gene BTG1. The miR-27a-3p/BTG1 axis may have potential implications for diagnostic and therapeutic approaches in CRC.

Introduction

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide (1). At present, the main treatments for CRC are surgery, radio- and chemotherapy (2). In China, CRC is a serious health problem due to its high rate of mortality, which represented the third highest cancer-associated mortality rate nationally in 2012 (3). Additionally, the mortality rate of CRC in China was 4-8 times higher than that in Europe and America in 2012 (4). Associated treatments and the prognosis for patients with CRC are poor. Advanced CRC is usually associated with invasion and metastasis of tumor cells and distant organ metastases, making diagnosis more difficult and greatly increasing the difficulty of treatment (5-7).

microRNAs (miRNAs/miRs) are a widely studied type of non-coding RNA and have been found to be the closely associated with the pathogenesis and efficacy of treatment of cancer (8). Numerous miRNAs have been demonstrated to serve important roles in the growth, differentiation and apoptosis of cancer cells (9). Alterations in the expression levels and functions of specific miRNAs may serve a key role in the genesis of diverse cancer types (10-14). Our previous study demonstrated that miR-27a-3p promoted gastric cancer cell proliferation in vitro as well as tumor growth in vivo (15). miR-27a has further been identified to act as an oncogene in MGC803 cells and knockdown of miR-27a inhibits cell growth and was determined to be dose-dependent (16). Certain studies have demonstrated that overexpression of miR-27a-3p significantly promotes growth of cancer cells in glioma (17), hepatocellular carcinoma (18), esophageal cancer (19), renal cell carcinoma (20) and nasopharyngeal carcinoma (21).
However, the role of miR-27a-3p in CRC and the underlying mechanisms are not well defined.

B-cell translocation gene (BTG)1, BTG2, BTG3, BTG4, transducer of ERBB2 and transducer of ERBB2 2 belong to the BTG family. As tumor suppressors, these proteins suppress cell proliferation and cell cycle progression, and induce differentiation (22,23). In particular, BTG1 has been reported to regulate cell cycle progression in a variety of cells, including breast cancer (24) and renal cell carcinoma cells (25) and has been suggested to be a potential therapeutic target (26-30). BTG1 expression is highest in the G1/G2 phases of the cell cycle and suppresses the progression of cells through G1 phase (31). While BTG1 exhibits nuclear localization, associated signals enable it to undergo nucleo-cytoplasmic shuttling (32). Notably, BTG1 has been reported to increase and enhance antisense Bcl-2-induced cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cells, and leukemia cell lines (33,34). It has been reported previously that BTG1 inhibits the proliferation, migration and invasion of gastric cancer cells (35,36), and is positively associated with increased expression of cyclin D1 and Bax, also known as anti-tumor protein (37). Overexpression of BTG1 serves an important role in CRC. Specifically, BTG1 expression reverses the aggressive phenotype and may be a candidate for gene therapy in CRC (38).

In the present study, miR-27a-3p was demonstrated to be overexpressed in human CRC tissues and colon cancer cell lines. Furthermore, the anti-proliferative gene BTG1 was predicted to be a direct target of miR-27a-3p. Therefore, the present study aimed to explore the association between miR-27a-3p and tumor growth, apoptosis, cell cycle distribution and the Ras/mitogen-activated extracellular signal-regulated kinase (MEK)/ERK signaling pathway. In summary, the hsa-miR-27a competitive inhibitor vector pEGFP-C1-miR-27a (-) was designed as a sponge of miR-27a with repeated binding sites complementary into the pEGFP-C1 vector. The sequences of the miR-27a sponge were: Forward, 5'-CCCAAG CTTACTGTGAAACTGTGAACGTGTAACACTTGAAAC TGTGAAACTGTGAACTAGAGC-3' and reverse, 5'-GCT CAATTTCTCAAGTTCTCATCGTTTACAG-3'. The construction of plasmids and respective sequences were performed as described previously (14). DNA was extracted from HCT-116 cells using TRizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and the coding region of BTG1 cDNA was amplified by PCR using 2X Hiieff™ PCR Master mix (Yeasen Biotech Co., Ltd.) according to the manufacturer's protocol. The thermocycling conditions were: 95°C for 1 min; followed by 35 cycles of 62°C for 30 sec, 94°C for 30 sec, 60°C for 50 sec and 72°C for 35 sec; and final extension at 72°C for 10 min. PCR products were purified from the agarose gel using a gel purification kit (Promega Corporation) at 3:1 ratio at 4°C for 16 h. Recombinant plasmids were then transferred to E. coli JM109 competent cells (cat. no. 9052; Takara Bio, Inc.). These cells were normally stored at -80°C. Prior to use, the E. coli JM109 competent cells were thawed on ice, and the pcDNA3.1 plasmid was mixed with the competent state at a ratio of 1:100, placed on ice for 30 min, then placed at 42°C for 60-90 sec, incubated for 2-3 min and diluted in LB medium (Hangzhou Baisi Biotechnology Co., Ltd.). An appropriate amount of mixed solution was applied, and subsequently E. coli were cultured overnight in LB medium-containing plates with 1% ampicillin (Beijing Solarbio Science & Technology Co., Ltd.) for amplification in a normal environment at 37°C. Specific primers were designed by PrimerPremier 6.0 (Premier Biosoft International). The primer sequences were: Forward, 5'-GGAAATTCCATCATCATT CTTCTCACCCGG-3' and reverse, 5'-CGACGGGTTTAA CCTGATACTAGTCTACAT-3'. Purified pcDNA-BTG1 recombinant plasmids were treated with EcoR I + Xho I restriction enzymes (Promega Corporation) at 37°C for 4 h. Digested products were separated using 1.5% agarose gel electrophoresis with ethidium bromide. DNA bands were identified by UV transilluminator (FR-200A; Shanghai Furi Science & Technology Co., Ltd.). Purified recombinant plasmids (1 µg/µl; A260/A280=1.8) were used to transfect cultured cells.

**Materials and methods**

**Tissues.** A total of 20 paired samples of human CRC and matched normal tissues were collected at Minhang Hospital (Affiliated to Fudan University) between December 2016 and February 2017. There were 13 males and 7 females, aged 38-62 years, included in the present study. The surgical procedures performed to obtain the tissues were laparoscopic radical resection of colorectal cancer. The lesion was considered to be normal tissue at a margin >5 cm from the edge of the tumor. The samples were stored in liquid nitrogen and February 2017. There were 13 males and 7 females, aged 38-62 years, included in the present study. The surgical procedures performed to obtain the tissues were laparoscopic radical resection of colorectal cancer. The lesion was considered to be normal tissue at a margin >5 cm from the edge of the tumor. The samples were stored in liquid nitrogen and subsequently stored at -80°C. The use of these tissues was approved by the Institutional Review Board of Minhang Branch, Zhongshan Hospital and Fudan University Shanghai Cancer Center, and signed informed consent was obtained from all participants.

**Plasmid construction.** The homo sapiens-miR-27a (hsa-miR-27a) expression vector pEGFP-C1-miR-27a (+), the hsa-miR-27a competitive inhibitor vector pEGFP-C1-miR-27a (-) and the vector pEGFP-C1 were obtained from the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. The hsa-miR-27a expression vector pEGFP-C1-miR-27a (+) contains primary-miR-27a and some of its flanking sequences (33). The sequences of the hsa-miR-27a were: Forward, 5'-CCG CTCGAGACCTGGCTGCTTAGGAAGTG-3' and reverse, 5'-GGCAAATCTTTGGTCTAGCCTTGTGC-3'. The hsa-miR-27a competitive inhibitor vector pEGFP-C1-miR-27a (-) was designed as a sponge of miR-27a with repeated binding sites complementary into the pEGFP-C1 vector. The sequences of the miR-27a sponge were: Forward, 5'-CCCCAG CTTACTGTGAAACTGTGAACGTGTAACACTTGAAAC TGTGAAACTGTGAACTAGAGC-3' and reverse, 5'-GCT CAATTTCTCAAGTTCTCATCGTTTACAG-3'. The construction of plasmids and respective sequences were performed as described previously (14). DNA was extracted from HCT-116 cells using TRizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and the coding region of BTG1 cDNA was amplified by PCR using 2X Hiieff™ PCR Master mix (Yeasen Biotech Co., Ltd.) according to the manufacturer's protocol. The thermocycling conditions were: 95°C for 1 min; followed by 35 cycles of 62°C for 30 sec, 94°C for 30 sec, 60°C for 50 sec and 72°C for 35 sec; and final extension at 72°C for 10 min. PCR products were purified from the agarose gel using a gel purification kit (Promega Corporation) at 3:1 ratio at 4°C for 16 h. Recombinant plasmids were then transferred to E. coli JM109 competent cells (cat. no. 9052; Takara Bio, Inc.). These cells were normally stored at -80°C. Prior to use, the E. coli JM109 competent cells were thawed on ice, and the pcDNA3.1 plasmid was mixed with the competent state at a ratio of 1:100, placed on ice for 30 min, then placed at 42°C for 60-90 sec, incubated for 2-3 min and diluted in LB medium (Hangzhou Baisi Biotechnology Co., Ltd.). An appropriate amount of mixed solution was applied, and subsequently E. coli were cultured overnight in LB medium-containing plates with 1% ampicillin (Beijing Solarbio Science & Technology Co., Ltd.) for amplification in a normal environment at 37°C. Specific primers were designed by PrimerPremier 6.0 (Premier Biosoft International). The primer sequences were: Forward, 5'-GGAAATTCCATCATCATT CTTCTCACCCGG-3' and reverse, 5'-CGACGGGTTTAA CCTGATACTAGTCTACAT-3'. Purified pcDNA-BTG1 recombinant plasmids were treated with EcoR I + Xho I restriction enzymes (Promega Corporation) at 37°C for 4 h. Digested products were separated using 1.5% agarose gel electrophoresis with ethidium bromide. DNA bands were identified by UV transilluminator (FR-200A; Shanghai Furi Science & Technology Co., Ltd.). Purified recombinant plasmids (1 µg/µl; A260/A280=1.8) were used to transfect cultured cells.

**Cell culture and transfection.** The human colon cancer lines HCT-116, HCT8, SW480, HT29, LOVO and Caco2 and the normal colorectal epithelial NCM460 cell line were purchased from the Type Culture Collection of the Chinese Academy of Sciences. All cell lines were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) containing 100 µM penicillin and 100 µM streptomycin (Thermo Fisher Scientific, Inc.) with 5% CO2 at 37°C in a humidified environment. Cell transfection was performed using Lipofectamine® 3000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. In brief, cultured...
cells were seeded into 6-well plates (5x10^4 cells/well). Then, 5 µg miR-27 mimic or 5 µg miR-27 inhibitor and 10 ml P3000™ (Invitrogen; Thermo Fisher Scientific, Inc.) reagent were dissolved in 120 µl DMEM each. Following incubation at room temperature for 20 min, both miRNA and P3000™ reagent were slowly added to cultured HCT-116 cells. After 24 h of incubation at 37°C, the culture medium was changed. The control (no miRNA transfection) and empty (transfected with empty pEGFP-C1) group transfections were performed in parallel. Transfection efficiency was determined by reverse transcription-quantitative PCR (RT-qPCR) after 48 h. Additional subsequent experiments were performed 48 h after the cells were transfected.

**RNA extraction and RT-qPCR.** Total RNA was extracted from HCT-116 cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Isolated miRNAs were reverse transcribed using TransScript miRNA First-Strand cDNA Synthesis SuperMix (Beijing Transgen Biotech Co., Ltd.). Briefly, 5 µl total RNA, 1 µl TransScript™ miRNA RT Enzyme mix (Beijing Transgen Biotech Co., Ltd.), 10 µl 2X TS miRNA Reaction mix (Beijing Transgen Biotech Co., Ltd.) and 4 µl RNase-free water were mixed according to the manufacturer's instructions and incubated for 1 h at 37°C, followed by incubation for 5 sec at 85°C. Subsequently, 0.2 µM forward primer and 10 µl 2X TransScript® Tip/Top Green qPCR SuperMix (Beijing Transgen Biotech Co., Ltd.) were mixed. The thermocycling conditions were: 94°C for 30 sec; followed by 45 cycles of 94°C for 5 sec, 60°C for 15 sec and 72°C for 15 sec; dissociation stage. The primer sequence for miR-27a-3p was 5'-TTCACTGCTATCGCCG-3'. miRNA was reverse transcribed with TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix (Beijing Transgen Biotech Co., Ltd.) and cDNA Synthesis SuperMix (Beijing Transgen Biotech Co., Ltd.) and 4 µl RNase-free water were mixed according to the manufacturer's instructions and incubated for 1 h at 37°C, followed by incubation for 5 sec at 85°C. Subsequently, 0.2 µM forward primer and 10 µl 2X TransScript® Tip/Top Green qPCR SuperMix (Beijing Transgen Biotech Co., Ltd.) were mixed. The thermocycling conditions were: 94°C for 30 sec; followed by 40 cycles of 94°C for 5 sec, 60°C for 15 sec and 72°C for 10 sec; return to room temperature. The comparative cycle threshold method (2^ΔΔCq) (39) was used to conduct the relative quantification of target genes and miRNAs (10). Levels of miRNA and mRNA were normalized against U6 snRNA and GAPDH, respectively. The primer sequences were: BTG1 forward, 5' -AGC TGA ACC TGT ATC TGC GG-3' and reverse, 5'-GAA TTC CTG TGA ACC TGT ATC TGC GG-3'; mRNA was reverse transcribed using TransScript miRNA First-Strand cDNA Synthesis SuperMix (Beijing Transgen Biotech Co., Ltd.); GAPDH forward, 5'-GGT GAA GGT CGG TAT GCA AAG GC-3'; GAPDH reverse, 5'-GGA ACG CTT CAC GTA TTT G-3'; and GAPDH forward, 5'-GGT GAA GGT CGG TAT GCA AAG GC-3'; U6 snRNA forward, 5'-ATT GGA ACG CTT CAC GTA TTT G-3'; and GAPDH reverse, 5'-GGT GAA GGT CGG TAT GCA AAG GC-3'. Transfection efficiency was determined by RT-qPCR.

**Western blot analysis.** RIPA lysis buffer (Beyotime Institute of Biotechnology) was used for cell lysis, the protein concentration was determined using a bicinchoninic acid assay (Thermo Fisher Scientific, Inc.) and 10% SDS-PAGE was used to separate cellular proteins (50 µg/lane). Subsequently, protein was transferred to a 0.45 µm PVDF filter at 200 V for 2 h. The subsequent western blot analysis was carried out as described previously (38). Following blocking in 3% BSA (A8020; Beijing Solarbio Science & Technology) for 2 h at room temperature, membranes were incubated with appropriate primary antibodies in dilution buffer (3% BSA; 1:1000 dilution) overnight at 4°C. β-actin was used as a loading control. Membranes were washed with TBS with 0.1% Tween-20 and incubated with horseradish peroxidase-conjugated secondary antibodies (cat. nos. 111-035-003 and 115-035-003; Jackson ImmunoResearch Laboratories, Inc.) at a dilution of 1:2,000 in 3% BSA for 3 h at room temperature. Protein expression was assessed by enhanced chemiluminescence (cat. no. D3030L1260; Shanghai Life iLab Biological Technology Co., Ltd.) and exposure to chemiluminescent film. LabWorks™ Image Acquisition (version 4.0; UVP, LLC) was used.

**Western blot analysis.** RIPA lysis buffer (Beyotime Institute of Biotechnology) was used for cell lysis, the protein concentration was determined using a bicinchoninic acid assay (Thermo Fisher Scientific, Inc.) and 10% SDS-PAGE was used to separate cellular proteins (50 µg/lane). Subsequently, protein was transferred to a 0.45 µm PVDF filter at 200 V for 2 h. The subsequent western blot analysis was carried out as described previously (38). Following blocking in 3% BSA (A8020; Beijing Solarbio Science & Technology) for 2 h at room temperature, membranes were incubated with appropriate primary antibodies in dilution buffer (3% BSA; 1:1000 dilution) overnight at 4°C. β-actin was used as a loading control. Membranes were washed with TBS with 0.1% Tween-20 and incubated with horseradish peroxidase-conjugated secondary antibodies (cat. nos. 111-035-003 and 115-035-003; Jackson ImmunoResearch Laboratories, Inc.) at a dilution of 1:2,000 in 3% BSA for 3 h at room temperature. Protein expression was assessed by enhanced chemiluminescence (cat. no. D3030L1260; Shanghai Life iLab Biological Technology Co., Ltd.) and exposure to chemiluminescent film. LabWorks™ Image Acquisition (version 4.0; UVP, LLC) was used.

**Proliferation and clone formation assays.** Using the MTT method, the proliferation of HCT-116 cells transfected with mimics/inhibitor was assessed after 5 days of transfection. Cultured cells were seeded into 96-well plates (1x10^4 cells/well), and after 0, 24, 48 and 72 h, 20 µl MTT solution (5 µg/ml) was added to each well and the plate was further incubated at 37°C for 4 h. Subsequently, the medium was aspirated and the wells were washed with PBS, allowed to dry for ~2 h and 200 µl DMSO (Sigma-Aldrich; Merck KGaA) was added to each well. The optical density was measured at 492 and 630 nm wavelength. Clone formation assays were performed as described previously (15).

**miR-27a-3p potential target gene prediction.** miRBase (version 20.0; http://www.mirbase.org/) was used to find the miRNA sequence. Subsequently, TargetMiner (https://www.isical.ac.in/~bioinfo_miu/TargetMiner.html), PicTar (https://pic.tar.nmd-berlin.de/cgi-bin/PicTar_vertebrate.cgi) (40) and TargetScan (version 7.1; www.targetscan.org) were used to predict the potential target genes of miR-27a-3p, and the intersection of the results was the target sequence.

**Flow cytometry analysis.** A Cell Cycle Assay kit (cat. no. FXP0211-200; 4A Biotech Co., Ltd.) was used according to the manufacturer's protocols and cell cycle distribution was analyzed by flow cytometry using a Fluorescence-activated Cell Sorting Vantage cytometer (BD Biosciences). In brief, the cells were harvested and fixed in ice-cold 70% (v/v) ethanol for 24 h at 4°C. The cell pellet was collected by centrifugation at 500 x g for 10 min at 4°C, resuspended in PBS, and stained with a mixture of RNase (10 µg/ml) and propidium iodide (50 µg/ml) in sodium citrate containing 0.5% Triton X-100 for 20 min in the dark at room temperature. The percentages of cells in the different cell cycle phases were analyzed
using WinMDI software (version 2.8; K. Trotter, The Scripps Research Institute, La Jolla, CA, USA).

Cells (1x10^5) were stained with the FITC Annexin-V Apoptosis Detection kit (R&D Systems, Inc.) according to the manufacturer's protocol. Briefly, cells from cultures were collected, washed with cold PBS, and then stained with Annexin-V-FITC (0.25 µg/ml) and propidium iodide for 15 min at room temperature in the dark. The stained cells were then analyzed by flow cytometry, acquiring 1x10^5 events gated according to a large gate established on cell forward and side scatters within 30 min of staining. The apoptotic cell ratio was analyzed by flow cytometry using a fluorescence-activated cell sorting vantage cytometer (BD Biosciences). FlowJo version 10.5.0 software (FlowJo LLC) was used for analysis.

TUNEL analysis. Cells (1x10^5) were plated in 6-well culture plates containing gelatin-coated cover slips. Adherent cells were transfected with mimics or inhibitor of miR-27a-3p and pcDNA-BTG1 for 48 h. Cells in the control group were not transfected. Treated cells and control cells were stained using a TUNEL FITC Apoptosis Detection kit (cat. no. C1088; Beyotime Institute of Biotechnology) according to the manufacturer's protocols. In brief, 1x10^5 cells were seeded on 6-well culture plates. Cells were washed with PBS for 5 min three times and fixed in 4% paraformaldehyde (cat. no. AR1069; Wuhan Boster Biological Technology, Ltd.) at 4˚C for 20 min. The cells were incubated with the TUNEL enzyme for 60 min at 3˚C. Finally, the fluorescent reaction was counterstained with DAPI (1:1,000 in PBS; Sigma-Aldrich; Merck KGaA) to dye the nucleus for 10 min at room temperature. Antifade mounting medium (cat. no. P0126; Beyotime Institute of Biotechnology) was used. Images from four fields of view were captured using a fluorescence microscope (magnification, x20; DMI3000B; Leica Microsystems, Inc.).

Statistical analysis. Data are presented as the mean ± SD. A Kruskal-Wallis-Test was performed to evaluate the significance of differences between the clinical tumor and normal samples, using a Steel Dwass post hoc test. Other data were analyzed using one-way ANOVA with a Tukey's HSD post hoc test. P<0.05 was considered to indicate a statistically significant difference, and P<0.01 was considered to indicate a statistically highly significant difference. Analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, Inc.).

Results

miR-27a-3p is overexpressed in CRC tissues and colon cancer cells. To determine the expression levels of miR-27a-3p, expression levels in 20 paired CRC and normal tissues were assessed by RT-qPCR. Compared with in the corresponding non-tumor samples, the expression of miR-27a-3p was markedly increased in the CRC tissues, with a fold-change >2.0 (Fig. 1A and B). In addition, consistent with the results for the clinical CRC samples, expression levels of miR-27a-3p were identified to be markedly upregulated in colon cancer cell lines (HCT-116, HCT8, SW480, HT29, LOVO and Caco2) compared with in the normal colorectal cell line NCM460 (Fig. 1C). Overall, these data indicated that expression of miR-27a-3p was increased in CRC tissues and colon cancer cell lines.

miR-27a-3p promotes colon cancer cell proliferation. To evaluate the role of miR-27a-3p in colon cancer cells, the miR-27a overexpression vector pEGFP-C1-miR-27a (+) was established by inserting a miR-27a precursor containing flanking
sequences into the pEGFP-C1 vector. Subsequently, the miR-27a expression vector or a competitive inhibitor plasmid, pEGFP-C1-miR-27a (-), were transfected into HCT-116 and NCM460 cells. RT-qPCR was used to verify the transfection efficiency. Results revealed that in pEGFP-C1-miR-27a (+) transfected cells, expression of miR-27a-3p was significantly upregulated, while in pEGFP-C1-miR-27a (-) transfected cells it was significantly decreased compared with the pEGFP-C1 transfected cells (Fig. 2A and B). The results of cell proliferation assays indicated that inhibiting miR-27a-3p expression reduced the growth rate of HCT-116 cells, whereas miR-27a-3p overexpression had no obvious effect on cell proliferation (Fig. 2C). Additionally, cell proliferation assays were used to detect the effect on NCM460 cells. It was revealed that miR-27a-3p overexpression promoted cell proliferation, although this effect was not observed to be statistically significant, while inhibiting miR-27a-3p expression had a significant effect on cell proliferation (Fig. 2D). Clone formation assays revealed the effect of inhibiting miR-27a-3p expression to inhibit the growth in HCT-116 cells and overexpression of miR-27a-3p could promote the growth of NCM460 cells (Fig. 2E and F). Since miR-27a-3p was overexpressed in CRC

Figure 2. miR-27-3a affects the proliferation and colony formation ability of colon cancer cells. Transfection efficiency in (A) NCM460 and (B) HCT-116 cells for pEGFP-C1-miR-27a (+) and pEGFP-C1-miR-27a (-) compared with the empty plasmid. (C) Growth curves of HCT-116 cells transfected with pEGFP-C1, pEGFP-C1-miR-27a (+) or pEGFP-C1-miR-27a (-). (D) Growth curves of NCM460 cells transfected with pEGFP-C1, pEGFP-C1-miR-27a (+) or pEGFP-C1-miR-27a (-). (E) Clone formation assay of NCM460 and HCT-116 cells transfected with miR-27a (+/-)/pEGFP-C1, respectively or pEGFP-C1. The number of microspheres was counted after 2 weeks. (F) Quantification of the clone formation assay comparing miR-27a-3p (+) or (-) with the empty vector in HCT-116 cells. Statistical analysis was performed using an ANOVA. All data are presented as the mean ± SD and are representative of three measurements. *P<0.05; **P<0.01; ***P<0.001 vs. control. (+), mimic; (-), inhibitor; miR-27a, microRNA-27a-3p.
tissues and cells, it could promote the proliferation of cancer cells. The MTT assay revealed that miR-27a-3p overexpression could promote the proliferation of NCW460 cells, indicating that overexpression of miR-27a-3p could promote the proliferation of normal cells and cancer cells. Inhibiting miR-27a-3p expression could reduce the proliferation of HCT-116 cells.
The role of miR-27a-3p in normal and cancer cells was investigated by overexpression and knockdown, respectively. Since miR-27a-3p overexpression had no effect on the growth of HCT-116 cells in the MTT assay, inhibition of miR-27a-3p also had no effect on the NCM460 cells in the MTT assay. Therefore, the clone formation assay with significant influence was selected.

miR-27a-3p and BTG1 regulate cell cycle progression and apoptosis in colon cancer cells. It has been reported that BTG1 acts as a tumor suppressor in several human malignant tumors, including CRC (38). It is also known to be a gene that induces apoptosis and inhibits proliferation (23). In order to improve the understanding of the functional mechanism of miR-27a-3p in colorectal tumorigenesis, direct targets of miR-27a-3p that may have biological functions need to be identified. Therefore, possible targets of miR-27a-3p were predicted using the target prediction programs TargetMiner (41), miRBase, PicTar (40) and TargetScan (42). BTG1, which is involved in cell proliferation, was indicated to be associated with the biological function of miR-27a-3p among hundreds of potential candidates, since its 3'-untranslated region contains a putative target sequence for miR-27a-3p (Fig. 3A). Transfection efficiency for the pcDNA‑BTG1 significantly induced apoptosis in HCT‑116 cells. Western blotting was performed to determine the protein levels of BTG1, Ras, MEK, p-MEK-1, ERK, P-ERK and c-Myc; β-actin was used as loading control. BTG1, B-cell translocation gene 1; MEK, mitogen-activated extracellular signal-regulated kinase; miR-27a-3p, microRNA 27a-3; P-, phospho-.

miR‑27a‑3p affects cell proliferation and apoptosis via the ERK/MEK signaling pathway. In order to further investigate how miR-27a-3p affected cell proliferation and apoptosis, the downstream signaling pathway mediated by BTG1 was studied. A previous study demonstrated that the ERK/MEK signaling pathway is a downstream pathway of BTG2 in gastric carcinoma (15). This was verified by western blot analysis in the present study. The results revealed that inhibition of miR-27a-3p and overexpression of BTG1 decreased the levels of p-ERK and p-MEK-1 but had no effect on ERK or MEK expression. Inhibition of miR-27a-3p and overexpression of BTG1 could increase BTG1 expression but decreased Ras and c-Myc expression (Fig. 4).

Discussion

CRC, a type of malignant tumor, is the second leading cause of cancer-associated mortality in Asia (43). It is also the third most commonly diagnosed type of cancer in men and the second in women worldwide (44). Despite advances in treatment modalities, the prognosis for patients with CRC has not significantly improved (45). miR-27a-3p has been identified as an onco-miRNA in several solid tumors, including breast (46), ovarian (47), pancreatic (48) and gastric (49) cancer. miR-27a has also been reported to be a key oncogenic component in CRC and miR-27a is overexpressed in CRC (49). miR-27a-3p may accelerate tumorigenesis by targeting several tumor suppressors, including BTG2 (15), F-box and WD repeat domain containing 7 (19), Yes associated protein 1 (50) and Wnt family member 3A (51). Regarding BTG1, it has been reported that the tumor suppressor enhances Hoxb9-mediated transcription and inhibits HeLa cell proliferation (52). Overexpression of BTG1 has been detected in apoptotic cells exhibiting DNA fragmentation and nuclear
condensation (53). Additionally, expression levels of BTG1 are decreased in kidney cancer and are associated with poor prognosis (54).

Our previous study (15) confirmed that overexpression of miR-27a-3p promoted gastric cancer cell proliferation in vitro as well as tumor growth in vivo and that BTG2 was a direct target of miR-27a-3p in gastric cancer. Zhao et al. (35) reported that BTG1 overexpression suppresses proliferation and cell cycle progression, and induces apoptosis, autophagy and differentiation in CRC cells. Therefore, the present study aimed to examine the effects of miR-27a-3p in CRC and verify BTG1 as a putative target of miR-27a-3p. The findings of the present study revealed that miR-27a-3p served as an oncogene in CRC. The expression levels of miR-27a-3p were significantly increased in CRC tissues compared with in the paired non-tumor tissues, and miR-27a-3p overexpression promoted the proliferation of HCT-116 cells. Furthermore, in cell proliferation experiments, the empty vectors had no effect on cell proliferation. miR-27a-3p mimic could reduce the proportion of cells in G1 phase. Additionally, transfection with miR-27a-3p mimic induced early apoptosis in HCT-116 cells.

Cyclin E and D activate cyclin dependent kinases (CDKs) during the cell cycle and serve an important regulatory role in the transition between G1 and S phases. Increased p21 and p27 binding to cyclin and CDK results in G1 arrest (55). Cyclin B1-CDK1 is involved in the early events of mitosis, and CDC25B activates CDC2 to initiate mitosis (56). In the present study, increased expression of miR-27a-3p was indicated to result in a lowered ratio of HCT-116 cells in the G1 phase. Additionally, the protein expression levels of cyclin E1 and D1 were evaluated.

Zhao et al. (35), assessed levels of apoptosis regulators, including Bcl-2, Bcl-xL, Bax, survivin, X-linked inhibitor of apoptosis, Akt1 and tumor suppressor p53 in HCT-15 cells overexpressing BTG1. Overexpression of BTG1 decreases Bcl-2 and Bax protein levels and upregulates p53 expression in the human esophageal cancer cell line ECA-109 (57), human thyroid cancer cell line FTC-133 (58), human breast tumors and breast cancer cells (MCF-7 and MDA-MB-231) (24), ovarian carcinoma cells OVCAR3 (59) and hematological malignancies cells (60). Furthermore, overexpression of BTG1 induces apoptosis of HCT-15 and HCT-116 cells, and decreases mitochondrial potential and increases senescence only in HCT-116 cells, suggesting differences in the mechanisms of apoptosis in these two cell lines (35). The induction of cell death requires activation of one or more members of the well-conserved caspases, a family of cysteinyl proteases (61,62). Following proteolytic activation from their proenzyme forms, caspases cleave various protein substrates, including lamins and PARP (63). PARP-1 is a member of the PARP family that is involved in differentiation, proliferation and tumor transformation (64). The present study investigated how the expression of miR-27a-3p affected colon cancer cell apoptosis. The current study suggested that BTG1 was a downstream target of miR-27a-3p. Different from previous studies, the present study investigated the effects of miR-27a-3p on proliferation and apoptosis of CRC cells by BTG1 overexpression. Transfection of HCT-116 cells with miR-27a-3p mimics revealed the decrease of BTG1 expression and the elevation of cleaved-caspase3 and PARP1 protein expression. The downregulated expression of apoptosis-associated genes and their encoded proteins may be the molecular basis of the difference in the apoptotic mechanism of BTG1-overexpressing cancer cells. To confirm this, the mechanism of BTG1-induced apoptosis will be investigated in future studies.

In human cancers, aberrant activation of the RAF/MEK/ERK signaling pathway is frequently observed. There has been increasing evidence revealing the importance of the RAF/MEK/ERK signaling pathway in tumorigenesis (65-67). The relatively high frequency of activating mutations of RAS (~20% of all human types of cancer), an upstream activator of the well-established RAF/MEK/ERK signaling cascade, as well as frequent activating mutations in the BRAF kinase gene (~7% of all human types of cancer) have been observed (68). Therefore, RAF and MEK kinases have received great attention among the numerous kinases (69,70).

miRNAs perform biological functions by suppressing their target genes (71). To explore the functional mechanism of miR-27a-3p in CRC, TargetMiner, miRBase, PicTar and TargetScan were used to predict possible targets of miR-27a-3p. From various potential candidates, BTG1 was selected, since it is accepted as a tumor suppressor and closely involved in cell proliferation (70,72). The present study revealed that transfection with miR-27a-3p inhibitor markedly upregulated the protein expression of BTG1 in HCT-116 cells, while transfection with miR-27a-3p mimic had the opposite effect. The present study also demonstrated that transfection with BTG1 had similar effects as transfection with the miR-27a-3p inhibitor, causing cell cycle arrest at G1 phase and inducing apoptosis in HCT-116 cells. Furthermore, inhibition of miR-27a-3p and overexpression of BTG1 decreased the level of p-ERK and p-MEK-1 in HCT-116 cells. All these results indicated that BTG1 may be a novel target of miR-27a-3p and may serve a tumor suppressor role in CRC. These findings may provide novel insights into the mechanisms underlying CRC and have potential applications in diagnosis and therapy.

In conclusion, the present study showed that downregulation of miR-27a-3p significantly inhibited proliferation and enhanced apoptosis in HCT-116 cells. miR-27a-3p may serve an important role in CRC cells by directly targeting BTG1.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Natural Science Research Project of Minhang District (grant no. 2017MHZ75).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

CS and YOC designed the study and prepared the figures. DPH and WYL collated the data and carried out data analyses. JWL drafted the manuscript and revised it critically for
important intellectual content, in addition they contributed to the interpretation of data. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Associated Institutional Review Board of Minhang Branch, Zhongshan Hospital, Fudan University and signed informed consent was obtained from all participants.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375: 1030-1047, 2010.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics. 2012. CA Cancer J Clin 65: 87, 2015.
3. Zhang Y, Shi J, Huang H, Ren J, Li N and Dai M: Burden of colorectal cancer in China. Zhonghua Liu Xing Bing Xue Za Zhi 36: 709-714, 2015 (In Chinese).
4. Carrie P: Declines in death from colorectal cancer in europe deemed major success. Cancer 124: 2876-2876, 2018.
5. Al-Sukhni E and Gallinger S: Treatment of colorectal cancer. Springer Netherlands, p809-812, 2010.
6. Coppejans F, Lopomo A, Spisni R and Migliore L: Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol 20: 943-956, 2014.
7. Ciombor KK, Wu C and Goldberg RM: Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med 66: 83-95, 2014.
8. Ju J: miRNAs as biomarkers in colorectal cancer diagnosis and prognosis. Bioanalysis 2: 901-906, 2010.
9. Chen X, Shi K, Wang Y, Song M, Zhou W, Tu H and Lin Z: Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. Oncotarget 6: 37544-37556, 2015.
10. Yang Q, Jie Z, Ye S, Li Z, Han Z, Wu J, Yang C and Jiang Y: Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility. Oncogene 33: 193-202, 2014.
11. Calin GA, Sevignani C, Dumitriu CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 10: 2999-3004, 2004.
12. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature 43: 834-838, 2005.
13. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006.
14. Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res 66: 7390-7394, 2006.
15. Zhou L, Liang X, Zhang L, Yang L, Nagao N, Wu H, Liu C, Lin S, Cai G and Liu J: MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget 7: 51943-51954, 2016.
16. Liu T, Tang H, Lang Y, Liu M and Li X: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273: 235-242, 2009.
17. Xu W, Liu M, Peng X, Zhou P, Zhou J, Xu K, Xu H and Jiang S: miR-24-3p and miR-27a-3p promote cell proliferation in glioma cells via cooperative regulation of MX11. Int J Oncol 42: 757-766, 2013.
18. Zhao N, Sun H, Sun B, Zhu D, Zhao X, Wang Y, Gu Q, Dong X, Liu F, Zhang Y and Li X: miR-27a-3p suppresses tumor metastasis and VM by down-regulating VE-cadherin expression and inhibiting EMT: An essential role for Twist-1 in HCC. Sci Rep 6: 23091, 2016.
19. Wu XZ, Wang KP, Song HJ, Xia JH, Jiang Y and Wang YL: MiR-27a-3p promotes esophageal cancer cell proliferation via F-box and WD repeat domain-containing 7 (FBXW7) suppression. Int J Clin Exp Med 8: 1555-1562, 2015.
20. Nakanobu W, Uemura M, Shimo M, Fujita K, Inagushi K, Ueda Y, Kitae K, Tsujikawa K and Nonomura N: Expression of miR-27a-3p is an independent predictive factor for recurrence in clear cell renal cell carcinoma. Oncotarget 6: 21645-21654, 2015.
21. Li L and Luo Z: Dysregulated miR-27a-3p promotes nasopharyngeal carcinoma cell proliferation and migration by targeting Mapk10. Oncol Rep 37: 2679-2687, 2017.
22. Winkler GS: The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 222: 66-72, 2010.
23. Sasajima H, Nakagawa K and Yokosawa H: Antiproliferative proteins of the BTG/Tob family are degraded by the ubiquitin-proteasome system. Eur J Biochem 269: 3596-3604, 2002.
24. Zou R, Zou ST, Wan JM, Li W, Li XL and Zhu W: BTG1 inhibits breast cancer cell growth through induction of cell cycle arrest and apoptosis. Oncol Rep 30: 2137-2144, 2013.
25. Liu C, Tao T, Xu B, Lu K, Zhang L, Jiang L, Chen S, Liu D, Zhang X, Cao N and Chen M: BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with proMT1. Oncol Lett 10: 619-624, 2015.
26. He J, Xu T, Shi Y, Ma C, Yang W, Fang L, Sun M, Wu W, Xiao F, Guo F, et al: MicroRNA 301A promotes intestinal inflammation and colitis-associated cancer development by inhibiting ubiquitin-proteasome system. Eur J Biochem 269: 1434-1448, 2012.
27. Lee AS, Kranzusch PJ and Cate JH: eIF3 targets cell proliferation by regulating messenger RNAs for translational activation or repression. Nature 522: 111-114, 2015.
28. Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroese Y, Sonneveld E, Hoogerbrugge PM, van Kessel AG, van Leeuwen FN and Kuiper RP: The origin and nature of tightly clustered BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multigenic evolution. PLoS Genet 8: e1002533, 2012.
29. Rouault JP, Rimokh R, Tessa C, Paranas G, Frenich M, Duret L, Garoccio M, Germain D, Samarut J and Magaud JP: BTG1, a member of a new family of antiproliferative genes. Embo J 11: 1663-1670, 1992.
30. Corjy MH, Kearney MA, Munzer DA, Diamond SM and Stollstenborg JK: Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab Invest 78: 47-58, 1998.
31. Nahta R, Yuan LX, Fiterman DJ, Zhang L, Symmans WF, Ueno NT and Esteva FJ: B cell translocation gene 1 contributes to multigenic BTG1 deletions in precursor B-cell acute lymphoblastic leukemia support a model of multigenic evolution. PLoS Genet 8: e1002533, 2012.
32. Zheng HC: BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers. World J Gastroenterol 20: 943-956, 2014.
33. Zheng HC: BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers. World J Gastroenterol 20: 943-956, 2014.
34. Zheng HC, Li J, Shen DF, Yang XF, Zhao S, Wu YZ, Takano Y, Sun HZ, Su RJ, Luo JS and Guo W: BTG1 expression correlates with pathogenesis, aggressive behaviors and prognosis of gastric cancer: A potential target for gene therapy. Oncotarget 19: 685-705, 2015.
35. Williams G and Stoeber K: The cell cycle and cancer. J Pathol 226: 352-364, 2012.
36. Zhao S, Chen SR, Yang XF, Shen DF, Takano Y, Su RJ and Zheng HC: BTG1 might be employed as a biomarker for carcinogenesis and a target for gene therapy in colorectal cancers. Oncotarget 8: 7502-7520, 2017.
37. Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q and Lu J: MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. Biochimie 94: 320-329, 2012.
38. Zou F, Mao R, Yang L, Lin S, Lei K, Zheng Y, Ding Y, Zhang P, Cai G, Liang X and Liu J: Targeted deletion of miR-139-5p enhances MAPK, NF-kB and STAT3 signaling and promotes intestinal inflammation and colorectal cancer. FEBS J 283: 1438-1452, 2016.
38. Bai Y, Qiao L, Xie N, Shi Y, Liu N and Wang J: Expression and prognosis analyses of the Tob/BTG antiproliferative (APRO) protein family in human cancers. PLoS One 12: e0184902, 2017.
39. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
40. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Prada E, Gunsalus KC, Stoffel M and Rajewsky N: Combinatorial microRNA target predictions. Nat Genet 37: 495-500, 2005.
41. Bandypadhyay S and Mitra R: TargetMiner: microRNA target prediction with systematic identification of tissue-specific negative examples. Bioinformatics 25: 2625-2631, 2009.
42. Xu W, San Lucas A, Wang Z and Liu Y: Identifying microRNA targets in different gene regions. BMC Bioinformatics 15 (Suppl 7): S4, 2014.
43. Ferrer RR, Ramirez M, Beckman LJ, Danao LL and Ashing-Giwa KT: The impact of cultural characteristics on colorectal cancer screening adherence among Filipinos in the United States: A pilot study. Psychooncology 20: 862-870, 2011.
44. Weitz J, Koch M, Debus J, Höhler T, Galle PR and Büchler MW: Colorectal cancer. Lancet 365: 1066-1066, 2005.
45. Wolpin BM and Mayer RJ: Systemic treatment of colorectal cancer. Lancet 365: 1066-1066, 2005.
46. Zhou S, Huang Q, Zheng S, Lin K, You J and Zhang X: miR-27a is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123, 2001.
47. Lin-Lin XU, et al: Effects of genistein on the growth of ovarian cancer cell SKOV3 by regulating miR-27a and target gene expression. Chin J Clin Pharmacol Ther 17: 1321-1326, 2012 (In Chinese).
48. Zhao Y, Wang P, Meng J, Ji Y, Xu D, Chen T, Fan R, Yu X, Yao J and Dong C: MicroRNA-27a-3p inhibits melanogenesis in melanoma cell lines and inhibits melanoma growth in vivo. Chin J Clin Pharmacol Ther 17: 1321-1326, 2012 (In Chinese).
49. Ma Y, Wu Z, Zhou Z, Wu L and Chen J: miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett 298: 150-158, 2010.
50. Choo KB, Soon YL, Nguyen PN, Hiew MS and Huang CJ: MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J Biomed Sci 21: 95, 2014.
51. Zeng G, Sun GG, Wang YD, Cheng YJ and Hu WN: BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma. Tumour Biol 35: 7779-7848, 2014.
52. Prévôt D, Voeltzel T, Birot AM, Morel AP, Rostan MC, Bensussan A, Steinhoff A and Devilder G: Inhibitors of apoptosis proteins (IAPs) as potential molecular targets for therapy of hematological malignancies. Curr Med Chem 11: 633-649, 2004.
53. Nicholson DW and Thornberry NA: Trends Biochem Sci 22: 999-306, 1997.
54. Salvesen GS and and Dixit VM: Caspases: Intracellular signaling by proteolysis. Cell 91: 443-446, 1997.
55. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, Hwang JJ, Chung CW, Jung YK and Oh BH: An anti apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123, 2001.
56. Nossa CW, Jain P, Tamiiselvam B, Gupta VR, Chen LF, Schreiber V, Desnoyers S and Blanke SR: Activation of the abundant nuclear factor poly(ADP-ribose) polymerase-1 by Helicobacter pylori. Proc Natl Acad Sci USA 106: 19998-20003, 2009.
57. Montagut C and Settleman J: Targeting the RAF-MEK-ERK pathway a therapeutic target in SCLC? J Thorac Oncol 11: 1233-1241, 2016.
58. Zhou K, Luo X, Wang Y, Cao D, Sun G: MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma. Biomed Pharmacother 93: 1025-1032, 2017.
59. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH Jr and Stephenson JR: Stephenson Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci 80: 4218-4222, 1983.
60. Montagut C and Settleman J: Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 283: 125-134, 2009.
61. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192-222, 2011.
62. Zhang H, Tang J, Li C, Kong J, Wang J, Wu Y, Xu E and Lai M: MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. Cancer Lett 350: 781-790, 2015.
63. Weng W, Liu N, Toyiyama Y, Kusunoki M, Nagasaka T, Fujitawa W, Wei Q, Qin H, Lin H, Ma Y and Goel A: Novel evidence for a PIWI-interacting RNA (piRNA) as an oncogenic mediator of disease progression, and a potential prognostic biomarker in colorectal cancer. Mol Cancer 17: 16, 2018.